Hanmi Group announced executive promotions reflecting achievements in research and development (R&D) and global business performance. Kim Na-young and Choi In-young, both executives who led the development of obesity drugs, have been promoted to vice president.
On July 2, Hanmi Group revealed that six executives were promoted in recognition of their innovative contributions across various sectors. This marks the first regular executive promotion since the establishment of a professional management system, with three promotions at Hanmi Science and three at Hanmi Pharmaceutical. The promotions focus on individuals who have excelled in key areas such as R&D, global business development, and healthcare.
This is the first executive appointment under CEO Hwang Sang-yeon, who took office earlier this year. The company stated that the changes reflect Hwang's commitment to leading business direction in future and innovative growth sectors.
In addition to Kim and Choi's promotions, Choi Jae-hyuk has been newly appointed as director of the Obesity and Metabolism Center within the Future Growth Division.
Vice President Kim Na-young played a crucial role in establishing the commercialization strategy for Hanmi Pharmaceutical's obesity and metabolic disease growth strategy, known as the H.O.P (Hanmi Obesity Pipeline) project, and in building a foundation for market entry.
Vice President Choi In-young and Executive Director Maeng Ji-woong have contributed to enhancing R&D capabilities by leading the development of next-generation innovative drugs and achieving global results. Their recent large-scale technology exports to global pharmaceutical companies have highlighted the competitiveness of Hanmi's proprietary platform technology, LAPSCOVERY. The obesity drug, epeglanatide, currently under development, also utilizes LAPSCOVERY technology.
Director Choi Jae-hyuk has been involved in R&D for obesity and metabolic disease pipelines at the Future Growth Division, contributing to the development of key pipelines, including the H.O.P project.
At Hanmi Science, Shin Jun-seob has been promoted to executive director, while Maeng Ji-woong has been promoted to executive director and Lee Jun-won to senior director.
Executive Director Shin Jun-seob has contributed to diversifying the business portfolio and enhancing organizational competitiveness through the medical device sector within the healthcare division. Senior Director Lee Jun-won has been recognized for leading the medical device planning team and achieving results in new business planning, product strategy development, and operational efficiency.
A Hanmi Group official stated, "This promotion reflects a performance-oriented approach that comprehensively considers achievements, expertise, and future growth potential. We plan to continue strengthening our competitiveness in global new drug development, technology exports, and healthcare new businesses."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.